Anthracyclines in haematology: Preclinical studies, toxicity and delivery systems

Blood Reviews

Volumn 11, Issue 4, 1997, Pages 201-223

  Richardson, D S ^a   Johnson, S A ^b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4' IODOESORUBICIN; ACLACINOMYCIN; ANNAMYCIN; ANTHRACYCLINE; ANTHRAQUINONE; ANTHRAQUINONE DERIVATIVE; BISANTRENE; CERAMIDE; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIRUBICIN; FAS ANTIGEN; GLYCOPROTEIN P; IDARUBICIN; LIPOSOME; MARCELLOMYCIN; MENOGARIL; MITOXANTRONE; PIRARUBICIN; ZORUBICIN;

ALOPECIA; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CARCINOGENICITY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CELL CYCLE; DIARRHEA; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DNA BINDING; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; LEUKOPENIA; MOUTH ULCER; MUCOSA INFLAMMATION; MULTIDRUG RESISTANCE; NAUSEA; NONHUMAN; PHENOTYPE; PHLEBITIS; PRIORITY JOURNAL; REVIEW; VOMITING;

EID: 0031468368     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(97)90020-5     Document Type: Article

References (273)

1. Di Marco A, Gaetani M, Orezzi B et al. 'Daunomycin', a new antibiotic of the rhodomycin group. Nature 1964; 201: 706-707.
2. Dubost M, Ganter P, Maral R et al. Rubidomycin: a new antibiotic with cytostatic properties. Cancer Chemother Rep 1964; 41: 35-45.
3. Di Marco A, Arcamone F, Zunino F. Daunomycin (Daunorubicin) and adriamycin and structural analogues: biological activity and mechanism of action. In: Gottlieb D, Shaw P D, eds). Antibiotics. Berlin, Springer Verlag, 1975; III: 101-128.
4. Di Marco A, Cassinelli G, Arcamone F. The discovery of daunorubicin. Cancer Treat Rep 1981; 65 (suppl 4): 3-8.
5. Tan C, Tasaka H, Yu K-P, Murphy ML, Karnofsky DA. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Cancer 1967; 20: 333-353.
6. Bonadonna G, Monfardini S, de Lena M, Fossati-Bellani F. Clinical evaluation of adriamycin, a new antitumour antibiotic. Br Med J 1969; 3: 503-506.
7. Workman P. Infusional anthracyclines: Is slower better? If so, why? Ann Oncol 1992; 3: 591-594.
8. Lown JW. Anthracycline and anthraquinone anticancer agents: current status and recent development. Pharmac Ther 1993; 60: 185-214.
9. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992; 119 (6): 670-686.
10. Waring M. Variation of the supercoils in closed circular DNA by binding of antibiotics and drugs: evidence for molecular models involving intercalation. J Mol Biol 1970; 54: 247-279.
11. Pigram WJ, Fuller W, Hamilton LD. Stereochemistry of intercalation: Interaction of daunomycin with DNA. Nature New Biol 1972; 235: 17-19.
12. Waring MJ. DNA Modification and Cancer. Ann Rev Biochem 1981; 50: 159-192.
13. Pullman B. Sequence specificity in the binding of antitumour anthracyclines to DNA: a success of theory. Anti-Cancer Drug Design 1991; 7: 95-105.
14. Arcamone F. Design and synthesis of anthracycline and distamycin derivatives as new, sequence specific, DNA-binding pharmacological agents. Gene 1994; 149: 57-61.
15. Zunino F, Gambetta R, DiMarco A. The inhibition in vitro of DNA polymerase and RNA polymerases by daunomycin and adriamycin. Biochem Pharmacol 1975; 24: 309-311.
16. Mizuno NS, Zakis B, Decker RW. Binding of daunomycin to DNA and the inhibition of RNA and DNA synthesis. Cancer Res 1975; 35: 1542-1546.
17. Ross WE, Glaubiger DL, Kohn KW. Protein-associated DNA breaks in cells treated with adriamycin or ellipticine. Biochim Biophys Acta 1978; 519: 23-30.
18. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226: 466-468.
19. Tewey KM, Chen GL, Nelson EM, Liu LF. Intercalative antitumour drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984; 259: 9182-9187.
20. Ross WE. DNA topoisomerases as targets for cancer therapy. Biochem Pharmacol 1985; 34: 4191-4195.
21. Fogelsong PD, Reckord C, Swink S. Doxorubicin inhibits human DNA topoisomerase I. Cancer Chemother Pharmacol 1992; 30: 123-125.
22. Bachur NR, Yu F, Johnson R, Hickey R, Wu Y, Malkas L. Helicase inhibition by anthracycline anticancer agents. Mol Pharmacol 1992; 41: 993-998.
23. Deffie AM, Batra JK, Goldenberg GJ. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukaemia cell lines. Cancer Res 1989; 49: 58-62.
24. Zwelling LA, Kerrigan D, Michaels S. Cytotoxicity and DNA strand breaks by 5-iminodaunorubicin in mouse leukaemia L1210 cells: comparison with adriamycin and 4′-(9-acridinylamino) methanesulfon-m-anisidide. Cancer Res 1982; 42: 2687-2691.
25. Nishiyama M, Horichi N, Mazouzi Z, Bungo M, Saijo N, Tapiero H. Can cytotoxic activity of anthracyclines be related to DNA damage? Anti-cancer Drug Design 1990; 5: 135-139.
26. Powis G. Anthracycline metabolism and free radical formation. In: Powis G, Prough R A, eds. Metabolism and Action of Anti-cancer Drugs. London, New York and Philadelphia: Taylor and Francis, 1987: 211-260.
27. Huffman DH, Bachur NR. Daunorubicin metabolism in acute myelocytic leukaemia. Blood 1972; 39: 637-643.
28. Schott B, Robert J. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture. Biochem Pharmacol 1989; 38: 4069-4074.
29. Kuffel MJ, Reid JM, Ames MM. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother Pharmacol 1992; 30: 51-57.
30. Bachur NR, Gordon SL, Gee MV. Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. Mol Pharmacol 1977; 13: 901-910.
31. Powis G, Appel PL. Relationship of the single-electron reduction potential of quinones to their reduction by flavoproteins. Biochem Pharmacol 1980; 29: 2567-2572.
32. Bachur NR, Gordon SL, Gee MV, Kon H. NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci USA 1979; 76: 954-957.
33. Pan S-S, Bachur NR. Xanthine oxidase catalyzed reductive cleavage of anthracycline antibiotics and free radical formation. Mol Pharmacol 1980; 17: 95-99.
34. Bachur NR, Gordon SL, Gee MV. A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res 1978; 38: 1745-1750.
35. Lown JW, Sim S-K, Majumdar KC, Chang R-Y. Strand scission of DNA by bound adriamycin and daunorubicin in the presence of reducing agents. Biochem Biophys Res Commun 1977; 76: 705-710.
36. Eliot H, Gianni L, Myers C. Oxidative destruction of DNA by the adriamycin-iron complex. Biochemistry 1984; 23: 928-936.
37. Muindi J, Sinha BK, Gianni L, Myers C. Thiol-dependent DNA damage produced by anthracycline-iron complexes. The structure-activity relationships and molecular mechanisms. Mol Pharmacol 1985; 27: 356-365.
38. Potmesil M, Kirschenbaum S, Israels M, Levin M, Khetarpal VK, Silber R. Relationship of adriamycin concentrations to the DNA lesions induced in hypoxic and euoxic L 1210 cells. Cancer Res 1983; 43: 3528-3533.
39. Potmesil M, Israels M, Silber R. Two mechanisms of adriamycin-DNA interaction in L1210. Biochem Pharmacol 1984; 33: 3137-3142.
40. Lane P, Vichi P, Bain DL, Tritton TR. Temperature dependence studies of adriamycin uptake and cytotoxicity. Cancer Res 1987; 47: 4038-4042.
41. Vichi P, Robison S, Tritton TR. Temperature dependence of adriamycin-induced DNA damage in L1210 cells. Cancer Res 1989; 49: 5575-5580.
42. Tritton TR, Yee G. The anticancer agent adriamycin can be actively cytotoxic without entering cells. Science 1982; 217: 248-250.
43. Tritton TR. Cell death in cancer chemotherapy: the case of adriamycin. In: Apoptosis: the Molecular Basis of Cell Death. Tomei LD, Cope FO, eds. Current Communications in Cell and Molecular Biology 3. New York: Cold Spring Harbor Laboratory Press, 1991.
44. Krishan A, Frei III E. Effect of adriamycin on the cell cycle traverse and kinetics of cultured human lymphoblasts. Cancer Res 1976; 36: 143-150.
45. Smith PJ, Rackstraw C, Cotter F. DNA fragmentation as a consequence of cell cycle traverse in doxorubicin- and idarubicin-treated human lymphoma cells. Ann Hematol 1994; 69: S7-S11.
46. Minderman H, Linssen P, Wessels J, Haanen C. Cell cycle related uptake, retention and toxicity of idarubicin, daunorubicin and doxorubicin. Anticancer Res 1993; 13: 1161-1166.
47. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-257.
48. Wyllie AH, Morris RG, Smith AL, Dunlop D. Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol 1984; 142: 67-77.
49. Arends MJ, Morris RG, Wyllie AH. Apoptosis: The role of the endonuclease. Am J Pathol 1990; 136: 593-608.
50. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980; 284: 555-556.
51. Oberhammer F, Wilson JW, Dive C et al. Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J 1993; 12: 3679-3684.
52. Walker PR, Weaver VM, Lach B, LeBlanc J, Sikorska M. Endonuclease activities associated with high molecular weight and internucleosomal DNA fragmentation in apoptosis. Exp Cell Res 1994; 213: 100-106.
53. Ling Y-H, Priebe W, Perez-Soler R. Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells. Cancer Res 1993; 53: 1845-1852.
54. Quillet-Mary A, Mansat V, Duchayne E et al. Daunorubicin-induced internucleosomal DNA fragmentation in acute myeloid cell lines. Leukemia 1996; 10: 417-425.
55. Hannun YA. The sphingomyelin cycle and the second messenger function of ceramide. J Biol Chem 1994; 269: 3125-3128.
56. Kolesnick R, Golde DW. The sphingomyelin pathway in tumour necrosis factor and interleukin-1 signaling. Cell 1994; 77: 325-328.
57. Obeid LM, Linardic CM, Karolak LA, Hannun YA. Programmed cell death induced by ceramide. Science 1993; 259: 1769-1771.
58. Cifone MG, DeMaria R, Roncaioli P et al. Apoptotic signalling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. Exp Med 1994; 177: 1547-1552.
59. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 1995; 82: 405-414.
60. Jaffrézou J-P, Levade T, Bettaïeb A et al. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J 1996; 15: 2417-2424.
61. Trauth BC, Klas C, Peters AM et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301-305.
62. Debatin K-M, Goldmann CK, Bamford R, Waldmann TA, Krammer PH. Monoclonal antibody-mediated apoptosis in adult T-cell leukaemia. Lancet 1990; 335: 497-500.
63. Debatin K-M, Goldmann CK, Waldmann TA, Krammer PH. APO-1-induced apoptosis of leukemia cells from patients with adult T-cell leukemia. Blood 1993; 81: 2972-2977.
64. Friesen C, Herr I, Krammer PH, Debatin K-M. Involvement of the CD95 (APO-I/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Medicine 1996; 2: 574-577.
65. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-365.
66. Casazza AM. Pre-clinical selection of new anthracyclines. Cancer Treat Rep 1986; 70: 43-49.
67. Wadler S, Fuks JZ, Wiernik PH. Phase I and II agents in cancer therapy: 1, anthracyclines and related compounds. J Clin Pharmacol 1986; 26: 491-509.
68. Arcamone F, Penco S. Relationship of structure to anticancer activity and toxicity of anthracyclines. Gann Monograph on Cancer Research 1989; 36: 81-94.
69. Cantoni O, Sestili P, Cattabeni F, Geroni C, Grandi M, Giuliani FC. Cellular and molecular pharmacology of 4′-epidoxorubicin in HeLa cells. Comparison with its parent drug doxorubicin. Cancer Res Clin Oncol 1989; 115: 373-378.
70. Cantoni O, Sestili P, Cattabeni F, Geroni C, Giuliani FC. Comparative effects of doxorubicin and 4′-epidoxorubicin on nucleic acid metabolism and cytotoxicity in a human tumor cell line. Cancer Chemother Pharmacol 1990; 27: 47-51.
71. Bagnara GP, Rocchi P, Bonsi L, Valvassori L, Marini M, Prodi G. The in vitro effect of epirubicin on human normal and leukemic hemopoietic cells. Anticancer Res 1987; 7: 1197-1200.
72. Kunimoto S, Miura K, Umezawa K et al. Cellular uptake and efflux and cytostatic activity of 4′-0-tetrahydropyranyladriamycin in adriamycin-sensitive and resistant tumour cell lines. J Antibiot 1984; 37: 1697-1702.
73. Munck JN, Fourcade A, Bennoun M, Tapiero H. Relationship between the intracellular level and growth inhibition of a new anthracyclin THP in Friend leukaemia cell variants. Leuk Res 1985; 9: 289-296.
74. Marie JP, Thevenin D, Zittoun R. In vitro sensitivity of leukemic clonogenic cells to four anthracyclines (adriamycin, daunorubicin, rubidazone and aclacinomycin) in human myeloid leukemia. Nouv Rev Fr Hematol 1985; 27: 163-167.
75. Formelli F, Di Marco A, Casazza AM, Pratesi G, Supino R, Mariani A. Biological properties of 4-demethoxydaunorubicin: in vitro and in vivo studies. Curr Chemother 1978; 1240-1242.
76. Supino R, Necco A, Dasdia T, Casazza AM, Di Marco A. Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxy derivatives of daunorubicin and adriamycin. Cancer Res 1977; 37: 4523-4528.
77. Fukushima T, Ueda T, Uchida M, Nakamura T. Action mechanism of idarubicin (4-demethoxydaunorubicin) as compared with daunorubicin in leukemic cells. Int J Hematol 1993; 57: 121-130.
78. Curtis JE, Minden MD, Minkin S, McCulloch EA. Sensitivities of AML blast stem cells to idarubicin and daunorubicin: a comparision with normal hematopoietic progenitors. Leukemia 1995; 9: 396-404.
79. Ballou RJ, Tseng MT. A study on the comparative efficacy of aclacinomycin-A and adriamycin on two solid tumours, in vitro and in vivo. Proc Am Assoc Cancer Res 1985; 26: 224 (abs 881).
80. Morin MJ, Sartorelli AC. Inhibition of glycoprotein biosynthesis by the inducers of HL-60 cell differentiation, aclacinomycin A and marcellomycin. Cancer Res 1984; 44: 2807-2812.
81. Schwartz JE, Salmon SE. Comparative in vitro activity of 4′-deoxy-4′-iododoxorubicin and other anthracyclines in the human tumor clonogenic assay. Invest New Drugs 1987; 5: 231-234.
82. Arcamone F. Properties of antitumor anthracyclines and new developments in their application: Cain Memorial Award Lecture. Cancer Res 1985; 45: 5995-5999.
83. Schott B, Vrignaud P, Ries C, Robert J, Londos-Gagliardi D. Cellular pharmacology of 4′-iodo-4′-deoxydoxorubicin. Br J Cancer 1990; 61: 543-547.
84. Adams EG, Bhuyan BK. Effects of 7-R-O-Methylnogarol (Menogaril) on L1210 cell progression in vitro and in vivo. Cancer Res 1986; 46: 6125-6130.
85. Wierzba K, Sugimato Y, Matsuo K et al. Menogaril, an anthracycline compound with a novel mechanism of action: cellular pharmacology. Jpn J Cancer Res 1990; 81: 842-849.
86. Ono K, Ikegami Y, Nishizawa M, Andoh T. Menogaril, an anthracycline derivative, inhibits DNA topoisomerase II by stabilizing cleavable complexes. Jpn J Cancer Res 1992; 83: 1018-1023.
87. Nafziger J, Auclair C, Florent J-C, Guillosson J-J, Monneret C. Pharmacological and physicochemical properties of a new anthracycline with potent antileukemic activity. Leuk Res 1991; 15: 709-713.
88. Andrivon W, Saucier J-M, Auclair C et al. Enhanced topoisomerase II-induced DNA breaks and free radical production by a new anthracycline with potent antileukemic activity. Leuk Res 1996; 20: 119-126.
89. Andrivon W, Callais F, Nafziger J, Monneret C, Guillosson J-J. A new anthracycline with potent antileukemic activity exhibits reduced mutagenicity. Mutation Res 1995; 344: 135-140.
90. Ling Y-H, Priebe W, Yang L-Y, Burke TG, Pommier Y, Perez-Soler R. In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes. Cancer Res 1993; 53: 1583-1589.
91. Consoli U, Priebe W, Ling Y-H et al. The novel anthracycline annamycin is not affected by p-glycoproteinelated multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukaemia cell lines. Blood 1996; 88: 633-644.
92. Johnston JB, Glazer RI. Cellular pharmacology of 3′-(4-morpholinyl) and 3′-(4-methoxy-1- piperidinyl) derivatives of 3′-deaminodaunorubicin in human colon carcinoma cells in vitro. Cancer Res 1983; 43: 1606-1610.
93. Johston JB, Habernicht B, Acton EM, Glazer RI. 3′-(3-cyano-4-morpholinyl)-3′-deaminoadriamycin: a new anthracycline with intense potency. Biochem Pharmacol 1983; 32: 3255-3258.
94. Sikic BI, Ehsan MN, Harker WG et al. Dissociation of antitumour potency from anthracycline cardiotoxicity in a doxorubicin analog. Science 1985; 228: 1544-1546.
95. Westendorf J, Groth G, Steinheider G, Marquardt H. Formation of DNA-adducts and induction of DNA-crosslinks and chromosomal aberrations by the new potent anthracycline antitumour antibiotics: morpholinodaunomycin, cyanomorpholinodaunomycin and cyanomorpholinoadriamycin. Cell Biol Toxicol 1985; 1: 87-101.
96. Wasserman K, Zwelling LA, Mullins TD et al. Effects of 3′-deamino-3′-(3-cyano-4-morpholinyl) doxorubicin and doxorubicin on the survival, DNA integrity, and nucleolar morphology of human leukaemia cells in vitro. Cancer Res 1986; 46: 4041-4046.
97. Jesson MI, Johnston JB, Anhalt CD, Begleiter A. Effects of 3′-(3-cyano-4-morpholinyl)-3′-deaminoadriamycin and structural analogues on DNA on HT-29 human colon carcinoma cells. Cancer Res 1987; 47: 5935-5938.
98. Peters JH, Gordon GR, Nolen HW, Tracey M, Thomas DW. Facile exchange of the cyano group in highly potent anticancer cyanomorpholinyl anthracyclines. Biochem Pharmacol 1988; 37; 357-361.
99. Cullinane C, Phillips DR. The DNA sequence specificity of cyanomorpholinoadriamycin. FEBS Lett 1991; 293: 195-198.
100. Wasserman K, Newman RA, Davis FM, Mullins TD, Rose KM. Selective inhibition of human ribosomal gene transcription by the morpholinyl anthracyclines cyanomorpholinyl- and morpholinyldoxorubicin. Cancer Res 1988; 48: 4101-4106.
101. Wasserman K, Markovits J, Jaxel C, Capranico G, Kohn KW, Pommier Y. Effects of morpholinyl doxorubicin, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II. Mol Pharmacol 1990; 38: 38-45.
102. Streeter DG, Johl JS, Gordon GR, Peters JH. Uptake and retention of morpholinyl anthracyclines by adriamycin-sensitive and -resistant P388 cells. Cancer Chemother Pharmacol 1986; 16: 247-252.
103. Mariani M, Capolongo L, Suarato A et al. Growth-inhibitory properties of novel anthracyclines in human leukemia cell lines expressing either Pgp-MDR or at-MDR. Invest New Drugs 1994; 12: 93-97.
104. Watanabe M, Komeshima N, Nakajima S, Tsuruo T. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells. Cancer Res 1988; 48: 6653-6657.
105. Coley HM, Twentyman PR, Workman P. 9-alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance. Eur J Cancer 1990; 26: 665-667.
106. Fry DW. Biochemical pharmacology of anthracenediones and anthrapyrazoles. Pharmac Ther 1991; 52: 109-125.
107. White RJ, Durr FE. Development of mitoxantrone. Invest New Drugs 1985; 3: 85-93.
108. Durr RE, Wallace RE, Citarella RV. Molecular and biochemical pharmacology of mitoxantrone. Cancer Treat Rev 1983; 10 (suppl B): 3-11.
109. Smith IE. Mitoxantrone (novatrone): a review of experimental and early clinical studies. Cancer Treat Rev 1983; 10: 103-115.
110. Durr FE. Biologic and biochemical effects of mitoxantrone. Semin Oncol 1984; 11 (suppl 1): 3-10.
111. Traganos F, Evenson DP, Staiano-Coico L, Darzynkiewicz Z, Melamed MR. Action of dihydroxyanthraquinone on cell cycle progression and survival of a variety of cultured mammalian cells. Cancer Res 1980; 40: 671-681.
112. Lown JW, Morgan AR, Yen SF, Wang YH, Wilson WD. Characteristics of the binding of the anticancer agents mitoxantrone and ametantrone and related structures to deoxyribonucleic acid. Biochemistry 1985; 24: 4028-4035.
113. Bowden GT, Roberts R, Alberts DS, Peng Y-M, Garcia D. Comparative molecular pharmacology in leukemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene. Cancer Res 1985; 45: 4915-4920.
114. Capolongo L, Belvedere G, D'Incalci M. DNA damage and cytotoxicity of mitoxantrone and doxorubicin in doxorubicin-sensitive and -resistant human colon carcinoma cells. Cancer Chemother Pharmacol 1990; 25: 430-434.
115. Novak RF, Kharasch ED. Mitoxantrone: propensity for free radical formation and lipid peroxidation - implications for cardiotoxicity. Invest New Drugs 1985; 3: 95-99.
116. Butler J, Hoey BM. Are reduced quinones necessarily involved in the antitumour activity of quinone drugs? Br J Cancer 1987; 55 suppl VIII: 53-59.
117. Drewinko B, Yang L-Y, Barlogie B, Trujillo JM. Comparative cytotoxicity of bisantrene mitoxantrone, ametantrone, dihydroxyanthracenedione, dihydroxyanthracenedione diacetate and doxorubicin on human cells in vitro. Cancer Res 1983; 43: 2648-2653.
118. Leopold WR, Nelson JM, Plowman J, Jackson RC. Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors. Cancer Res 1985; 45: 5532-5539.
119. Graham MA, Newell DR, Butler J, Hoey B, Patterson LH. The effect of the anthrapyrazole antitumour agent CI941 on rat liver microsome and cytochrome P-450 reductase mediated free radical processes. Biochem Pharmacol 1987; 36: 3345-3351.
120. Judson IR. Anthrapyrazoles: true successors to the anthracyclines? Anti-cancer Drugs 1991; 2: 223-231.
121. Judson IR. The anthrapyrazoles: a new class of compounds with clinical activity in breast cancer. Semin Oncol 1992; 19: 687-694.
122. Inaba M, Kobayashi H, Sakurai Y, Johnson RK. Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukaemia. Cancer Res 1979; 39: 2200-2203.
123. Riordan JR, Ling V. Purification of p-glycoprotein from plasma membrane vesicles of chinese hamster ovary cell mutants with reduced colchicine permeability. J Biol Chem 1979; 254: 12701-12705.
124. Kartner N, Riordan JR, Ling V. Cell surface p-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983; 221: 1285-1288.
125. Booser DJ, Hortobagyi GN. Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs 1994; 47: 223-258.
126. Gros P, Ben Neriah Y, Croop JM, Housman DE. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986; 323: 728-731.
127. Kartner N, Evernden-Porelie D, Bradley G, Ling V. Detection of p-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 1985; 316: 820-823.
128. Gros P, Croop J, Housman D. Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 1986; 47: 371-380.
129. Borst P, Schinkel AH, Smit JJM et al. Classical and novel forms of multidrug resistance and the physiological functions of p-glycoproteins in mammals. Pharmac Ther 1993; 60: 289-299.
130. Endicott JA, Ling V. The biochemistry of p-glycoprotein-mediated multidrug resistance. Ann Rev Biochem 1989; 58: 137-171.
131. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product p-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735-7738.
132. Cordon-Cardo C, O'Brien JP, Casals D et al. Multidrug-resistance gene (p-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989; 86: 695-698.
133. Smeets M, Raymakers R, Vierwinden G et al. A low but functionally significant MDR1 expression protects primitive haemopoietic progenitor cells from anthracycline toxicity. Br J Haematol 1997; 96: 346-355.
134. Priebe W, Perez-Soler R. Design and tumor targeting of anthracyclines able to overcome multidrug resistance: a double-advantage approach. Pharmac Ther 1993; 60: 215-234.
135. Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukaemia cells. Blood 1992; 79: 3267-3273.
136. Michieli M, Michelutti A, Damiani D et al. A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives. Leuk Lymphoma 1993; 9: 255-264.
137. Coley HM, Twentyman PR, Workman P. The efflux of anthracyclines in multidrug-resistant cell lines. Biochem Pharmacol 1993; 46: 1317-1326.
138. Testi R, Mattii L, di Simone D et al. Evaluation of resistance index of several anticancer agents on parental and resistant P-388 cell lines. Leuk Res 1995; 19: 257-261.
139. Zhang XP, Ritke MK, Yalowich JC et al. P-glycoprotein mediates profound resistance to bisantrene. Oncol Res 1994; 6: 291-301.
140. Tsuruo T, Iida H, Tsukagashi S, Sakurai Y. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 1982; 42; 4730-4733.
141. Rogan AM, Hamilton TC, Young RC, Klecker Jr RW, Ozols RF. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 1984; 224: 994-996.
142. Bellamy WT, Dalton WS, Kailey JM et al. Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. Cancer Res 1988; 48: 6303-6308.
143. Boiron J-M, Belloc F, Montastruc M et al. Flow cytometric study of idarubicin and daunorubicin accumulation and the effect of verapamil in leukaemic cell lines and fresh cells from patients with acute non-lymphoblastic leukaemia. Leuk Res 1994; 18: 313-318.
144. Gibby EM, Boyse O, Hill BT. Selective interactions of verapamil with anthraquinones in adriamycin-sensitive and -resistant murine and human tumour cell lines in vitro. Cancer Chemother Pharmacol 1987; 20: 5-7.
145. Safa AR, Glover CJ, Sewell JL, Meyers MB, Biedler JL, Felsted RL. Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers. J Biol Chem 1987; 262: 7884-7888.
146. Muller C, Bailly J-D, Goubin F, Laredo J, Jaffrézou J-P, Bardier C, Laurent G. Verapamil decreases p-glycoprotein expression in multidrug-resistant human leukaemic cell lines. Int J Cancer 1994; 56: 749-754.
147. Meador J, Sweet P, Stupecky M et al. Enhancement by cyclosporin A of daunorubicin efficacy in ehrlich ascites carcinoma and murine hepatoma 129. Cancer Res 1987; 47: 6216-6219.
148. Coley HM, Twentyman PR, Workman P. Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A. Cancer Chemother Pharmacol 1989; 24: 284-290.
149. Coley HM, Twentyman PR, Workman P. Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A. Biochem Pharmacol 1989; 38: 4467-4475.
150. Colombo T, Gonzalez Paz O, D'Incalci M. Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia. Br J Cancer 1996; 73: 866-871.
151. Michieli M, Damiani D, Michelutti A et al. Restoring uptake and retention of daunorubicin and idarubicin in p170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin A and SDZ PSC 833. Haematologica 1994; 79; 500-507.
152. Jiang X-R, Kelsey SM, Wu Y-L, Newland AC. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemia cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833. Br J Haematol 1995; 90: 375-383.
153. Tapiero H, Boulé D, Trincal G, Fourcade A, Lampidis TJ. Potentiation of adriamycin accumulation and effectiveness in adriamycin-resistant cells by aclacinomycin A. Leuk Res 1988; 12: 411-418.
154. Millot J-M, Rasoanaivo TDW, Morjani H, Manfait M. Role of the aclacinomycin A-doxorubicin association in reversal of doxorubicin resistance in K562 tumour cells. Br J Cancer 1989; 60: 678-684.
155. Kurosawa M, Okabe M, Hara N et al. Reversal effect of itraconazole on adriamycin and etoposide resistance in human leukemia cells. Ann Hematol 1996; 72: 17-21.
156. Berman E, Adams M, Duigou-Osterndorf R, Godfrey L, Clarkson B, Andreeff M. Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood 1991; 77: 818-825.
157. Berman E, McBride M, Tong W. Comparative activity of tamoxifen and N-desmethyltamoxifen in human multidrug resistant leukemia cell lines. Leukemia 1994; 8: 1191-1196.
158. McGrath T, Latoud C, Arnold ST, Safa AR, Felsted RL, Center MS. Mechanisms of multidrug resistance in HL60 cells. Biochem Pharmacol 1989; 38: 3611-3619.
159. Marquardt D, McCrone S, Center MS. Mechanisms of multidrug resistance in HL-60 cells; detection of resistance-associated proteins with antibodies against synthetic peptides that correspond to the deduced sequence of P-glycoprotein. Cancer Res 1990; 50: 1426-1430.
160. Cole SPC, Bhardwaj G, Gerlach JH et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-1653.
161. Krishnamachary N, Center MS. The MRP gene associated with a non-p-glycoprotein multidrug resistance encodes a 190 kDa membrane bound glycoprotein. Cancer Res 1993; 53: 3658-3661.
162. Nagasawa K, Natazuka T, Chihara K et al. Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells. Cancer Chemother Pharmacol 1996; 37: 297-304.
163. Davey MW, Hargrave RM, Davey RA. Comparison of drug accumulation in p-glycoprotein-expressing and MRP-expressing human leukaemia cells. Leuk Res 1996; 20: 657-664.
164. Ross DD, Doyle LA, Schiffer CA et al. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute leukemia (AML) patients. Leukemia 1996; 10: 48-55.
165. Glisson B, Gupta R, Hodges P, Ross W. Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracelluar target. Cancer Res 1986; 46: 1939-1942.
166. Capranico G, Riva A, Tinelli S, Dasdia T, Zunino F. Markedly reduced levels of anthracycline-induced DNA strand breaks in resistant P388 leukaemia cells and isolated nuclei. Cancer Res 1987; 47: 3752-3756.
167. Potmesil M, Hsiang Y-H, Liu L F et al. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res 1988; 48: 3537-3543.
168. Deffie AM, Batra JK, Goldenberg GJ. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 1989; 49: 58-62.
169. Harker WG, Slade DL, Drake FH, Parr RL. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase IIβ isoform. Biochemistry 1991; 30: 9953-9961.
170. Lutzky J, Astor MB, Taub RN et al. Role of glutathione and dependent enzymes in anthracycline resistant HL60/AR cells. Cancer Res 1989; 49: 4120-4125.
171. Benjamin RS, Wiernik PH, Bachur NR. Adriamycin chemotherapy - efficacy, safety and pharmacologic basis of an intermittent single high-dosage schedule. Cancer 1974; 35: 19-27.
172. Lu K, Savaraj N, Kavanagh J et al. Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). Cancer Chemother Pharmacol 1986; 17: 143-148.
173. Berman E, Heller G, Santorsa JA et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77: 1666-1674.
174. Wiernik PH, Banks PLC, Case Jr DC et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukaemia. Blood 1992; 79: 313-319.
175. Vogler WR, Velez-Garcia E, Weiner RS et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukaemia: A Southeastern Cancer Study Group study. J Clin Oncol 1992; 10: 1103-1111.
176. Minderman H, Linssen P, van der Lely N et al. Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state. Leukemia 1994; 8: 382-387.
177. Crossley RJ. Clinical safety and tolerance of mitoxantrone. Semin Oncol 1984; 11 (Suppl 1): 54-58.
178. Posner LE, Dukart G, Goldberg J, Bernstein T, Cartwright K. Mitoxantrone: an overview of safety and toxicity. Invest New Drugs 1985; 3: 123-132.
179. Thompson EN, Sarab-Al-Nakeeb. Effect of leukaemia therapy on neutrophil chemotaxis. J Clin Pathol 1981; 34: 371-376.
180. Vaudaux P, Kiefer B, Forni M, Joris I, Majno G, Waldvogel FA. Adriamycin impairs phagocytic function and induces morphologic alterations in human neutrophils. Cancer 1984; 54: 400-410.
181. Mantovani A. In vitro in vivo cytotoxicity of adriamycin and daunomycin for murine macrophages. Cancer Res 1977; 37: 815-820.
182. Marquardt H, Philips FS, Sternberg SS. Tumorigenicity in vivo and induction of malignant transformation and mutagenesis in cell cultures by adriamycin and daunomycin. Cancer Res 1976; 36: 2065-2069.
183. Vallagussa PA, Bonadonna G. Carcinogenic effects of cancer treatment. In: Peckham M, Pinedo H, Veronesi U, eds. Oxford Textbook of Oncology. Oxford: Oxford University Press, 1995: 2348-2358.
184. Pederson-Bjergaard J, Philip P. Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic for myelodysplasia and leukaemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood 1991; 78: 1147-1148.
185. Kaldor JM, Day NE, Pettersson F et al. Leukemia following chemotherapy for ovarian cancer. N Engl J Med 1990; 322: 1-6.
186. Pedersen-Bjergaard J, Sigsgaard TC, Nielsen D et al. Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4 epidoxorubicin and cisplatin or cyclophosphamide for breast cancer. J Clin Oncol 1992; 10: 1444-1451.
187. Sandoval C, Pin CH, Bowman LC et al. Secondary acute myeloid leukaemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors and irradiation. J Clin Oncol 1993; 11: 1039-1045.
188. Satterwhite B, Zimm S. The use of scalp hypothermia in the prevention of doxorubicin-induced hair loss. Cancer 1984; 54: 34-37.
189. Tollenaar RA, Liefers GJ, Repelaer van Driel OJ, van-de Velde CJ. Scalp cooling has no place in the prevention of alopecia in adjuvant chemotherapy for breast cancer. Eur J Cancer 1994; 30A: 1448-1453.
190. Rudolph R, Stein RS, Pattillo RA. Skin ulcers due to adriamycin. Cancer 1976; 38: 1087-1094.
191. Averbuch SD, Gaudiano G, Koch TH, Bachur NR. Doxorubicin-induced skin necrosis in the swine model: protection with a novel radical dimer. J Clin Oncol 1986; 4: 88-94.
192. Cassady JR, Richter MP, Piro AJ, Jaffe N. Radiation-adriamycin interactions: preliminary clinical observations. Cancer 1975; 36: 946-949.
193. Greco FA, Brereton HD, Kent H, Zimbler H, Merrill J, Johnson RE. Adriamycin and enhanced radiation reaction in normal esophagus and skin. Ann Intern Med 1976; 85: 294-298.
194. Bressole F, Jacquet J-M, Galtier M, Jourdan J, Doradio D, Rossi J-F. Doxorubicin and doxorubicinol plasma concentrations and excretion in parotid saliva. Cancer Chemother Pharmacol 1992; 30: 215-218.
195. Morelli D, Ménard S, Colnaghi MI, Balsari A. Oral administration of anti-doxorubicin monoclonal antibody prevents chemotherapy-induced gastrointestinal toxicity in mice. Cancer Res 1996; 56: 2082-2085.
196. Mimnaugh EG, Trush MA, Bhatnagar M, Gram TE. Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug adriamycin. Biochem Pharmacol 1985; 34: 847-856.
197. Hershko C, Link G, Tzahor M, Pinson A. The role of iron and iron chelators in anthracycline cardiotoxicity. Leuk Lymphoma 1993; 11: 207-214.
198. Hershko C, Link G, Tzahor M et al. Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture. J Lab Clin Med 1993; 122: 245-251.
199. Minolti G, Cavaliere AF, Mordente A et al. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. J Clin Invest 1995; 95: 1595-1605.
200. Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 1980; 65: 128-135.
201. Goormaghtigh E, Pollakis G, Ruysschaert JM. Mitochondrial membrane modifications induced by adriamycin-mediated electron transport. Biochem Pharmacol 1983; 32: 889-893.
202. 2+ exchange of dog heart sarcolemmal vesicles. FEBS Lett 1981; 130: 184-186.
203. Boucek Jr. RJ, Olson RD, Brenner DE, Oganuburnmi EM, Inui M, Fleischer S. The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions. J Biol Chem 1987; 262: 15851-15856.
204. Olson RD, Mushlin PS, Brenner DE et al. Doxorubicin cardiotoxicity may be caused by its metabolite doxorubicinol. Proc Natl Acad Sci USA 1988; 85: 3585-3589.
205. Santostasi G, Kutty RK, Krishna G. Increased toxicity of anthracycline antibiotics induced by calcium entry blockers in cultured cardiomyocytes. Toxicol App Pharmacol 1991; 108: 140-149.
206. Papoian T, Lewis W. Anthracyclines selectively decrease α cardiac actin mRNA abundance in the rat heart. Am J Pathol 1992; 141: 1187-1195.
207. Malpas JS, Bodley Scott R. Rubidomycin in acute leukaemia in adults. Br Med J 1968; 3: 227-229.
208. Malpas JS, Bodley Scott R. Daunorubicin in acute myelocytic leukaemia. Lancet 1969; i: 469-470.
209. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathological analysis of adriamycin cardiotoxicity. Cancer 1973; 32: 302-314.
210. Wortman JE, Lucas Jr VS, Schuster EW, Thiele D, Logue GL. Sudden death during doxorubicin administration. Cancer 1979; 44: 1588-1591.
211. Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM. Daunomycin-induced cardiotoxicity in children and adults. Am J Med 1977; 62: 200-208.
212. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC. Early anthracycline cardiotoxicity. Am J Med 1978; 65: 823-832.
213. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808-815.
214. Steinherz LJ, Steinherz PG, Tan CTC, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266: 1672-1677.
215. Johnson GL, Moffett CB, Geil JD, Greenwood MF, Noonan JA. Late echocardiographic findings following childhood chemotherapy with normal serial cardiac monitoring. J Pediatr Hematol Oncol 1996; 18: 72-75.
216. Larsen RL, Jakacki RI, Vetter VL, Meadows AT, Silber JH, Barber G. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 1992; 70: 73-77.
217. Von Hoff DD, Layard M. Risk factors for development of daunorubicin cardiotoxicity. Cancer Treat Rep 1981; 65 (Suppl 4): 19-23.
218. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-717.
219. Steinherz LJ, Graham T, Hurwitz R et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the cardiology committee of the childrens cancer study group. Pediatrics 1992; 89: 942-949.
220. Lipshultz SE, Sanders SP, Goorin AM, Krischer JP, Sallan SE, Colan SD. Monitoring for anthracycline cardiotoxicity. Pediatrics 1994; 93: 433-437.
221. Davis LE, Brown CEL. Peripartum heart failure in a patient previously treated with doxorubicin. Obstet Gynecol 1988; 71: 506-508.
222. Carlson RW. Reducing the cardiotoxicity of the anthracyclines. Oncology (Huntingt) 1992; 6: 95-104.
223. Basser RL, Green MD. Strategies for prevention of anthracycline cardiotoxicity. Cancer Treat Rev 1993; 19: 57-77.
224. Hale JP, Lewis IJ. Anthracyclines: cardiotoxicity and its prevention. Arch Dis Child 1994; 71: 457-462.
225. Miller AA, Salewski E. Prospects for pirarubicin. Med Pediatr Oncol 1994; 22: 261-268.
226. McGovren JP, Nelson KG, Lassus M, Cradock JC, Plowman J, Cristopher JP. Menogaril: a new anthracycline agent entering clinical trials. Invest New Drugs 1984; 2: 359-367.
227. Mazurek C, Dutcher JP, Schwartz EL, Garl S, Benson L, Wiernik PH. Phase I clinical and pharmacokinetic study of menogaril (7-con-O-methylnogarol) in previously treated patients with acute leukaemia. Invest New Drugs 1993; 11: 313-322.
228. Spadea A, Petti MC, Aloespiriti MA et al. Bisantrene in relapsed and refractory acute myelogenous leukemia. Leuk Lymphoma 1993; 9: 217-220.
229. Spiegel RJ, Blum RH, Levin M et al. Phase I clinical trial of 9, 10-anthracene dicarboxaldehyde (Bisantrene) administered in a 5-day schedule. Cancer Res 1982; 42: 354-358.
230. Chan-Lam D, Copplestone JA, Prentice A, Price R, Johnson S, Philips M. Idarubicin cardiotoxicity in acute myeloid leukaemia. Lancet 1992; 340: 185-186.
231. Dutcher JP, Leong T, Makary MZ et al. A phase II study of menogaril (7R-O-methylnogarol) in patients with relapsed/refractory acute myeloid leukaemia: a study of the Eastern Cooperative Oncology Group. Leukemia 1995; 9: 1638-1642.
232. Anderlini P, Benjamin RS, Wong FC et al. Idarubicin cardiotoxicity: a retrospective study in acute meyloid leukemia and myelodysplasia. J Clin Oncol 1995; 13: 2827-2834.
233. Janmohammed R, Milligan DW. Mitoxantrone induced congestive heart failure in patients previously treated with anthracyclines. Br J Haematol 1989; 71: 292-293
234. Torti FM, Bristow MR, Howes AE et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Ann Intern Med 1983; 99: 745-749.
235. Legha SS, Benjamin RS, Mackay B et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133-139.
236. Shapira J, Gotfried M, Lishner M, Ravid M. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. Cancer 1990; 65: 870-873.
237. Muller C, Chatelut E, Gualano V et al. Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukaemia: comparison of bolus administration and continuous infusion. Cancer Chemother Pharmacol 1993; 32: 379-384.
238. Green MD, Alderton P, Gross J, Muggia FM, Speyer JL. Evidence of the selective alteration of anthracycline activity due to modulation by ICRF-187 (ADR-529). Pharmac Ther 1990; 48: 61-69.
239. Koning J, Palmer P, Franks CR et al. Cardioxane - ICRF-187. Towards anticancer drug specificity through selective toxicity reduction. Cancer Treat Rev 1991; 18: 1-19.
240. Alderton PM, Gross J, Green MD. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res 1992; 52: 194-201.
241. Pouna P, Bonoron-Adèle S, Robert J. Protective effect of cardioxane (ICRF-187, ADR-529) on doxorubicin-induced cardiotoxicity as studied with the isolated perfused rat heart. Proc 9th NCI-EORTC Symposium on new drugs in cancer therapy. Amsterdam 1996; 116, abs 408.
242. Bu'Lock FA, Gabriel HM, Oakhill A, Mott MG, Martin RP. Cardioprotection by ICRF-187 against high dose anthracycline toxicity in children with malignant disease. Br Heart J 1993; 70: 185-188.
243. Wexler LH, Andrich MP, Verson D et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996; 14: 362-372.
244. Speyer JL, Green MD, Zeleniuch-Jacquotte A et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10: 117-127.
245. Van Acker SABE, Kramer K, Grimbergen JA, van den Berg D-J, van der Vijgh WJF, Bast A. Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity. Br J Pharmacol 1995; 115: 1260-1264.
246. Van Acker S, Boven E, Kramer K, Grimbergen J, Bast A, van der Vijgh W. The new cardioprotector 7-monohydroxyethylrutoside does not affect the antitumour activity of doxorubicin. Proc 9th NCI-EORTC Symposium on new drugs in cancer therapy. Amsterdam 1996; 116, abs 409.
247. Cassidy J. Pharmacokinetics, targeting and delivery systems in anthracycline-resistant cancers. Eur J Cancer 1995; 31A (suppl 7): S18-S20.
248. Lagueux J, Pagé M, Delorme F. Daunorubicin-albumin copolymer targeting to leukemic cells in vitro and in vivo. Semin Oncol 1984; 11 (suppl 3): 59-63.
249. Trouét A, Jollès G. Targeting of daunorubicin by association with DNA or proteins: a review. Semin Oncol 1984; 11 (suppl 3): 64-72.
250. Cassidy J, Duncan R, Morrison GJ et al. Activity of N-(2-hydroxypropyl) methacrylamide copolymers containing daunomycin against a rat tumour model. Biochem Pharmacol 1989; 38: 875-879.
251. Houba PHJ, Leenders RGG, Boven E, Scheeren JW, Pinedo HM, Haisma HJ. Characterization of novel daunorubicin (DNR) prodrugs activated by human β-glucuronidase for use in antibody-directed enzyme prodrug therapy (ADEPT). Proc 9th NCI-EORTC symposium on new drugs in cancer therapy. Amsterdam, 1996; 56, abs 189.
252. Rahman A, Fumagalli A, Goodman A, Schein PS. Potential of liposomes to ameliorate anthracycline-induced cardiotoxicity. Semin Oncol 1984; 11(Suppl 3): 45-55.
253. Perez-Soler R. Liposomes as carriers of antitumor agents: toward a clinical reality. Cancer Treat Rev 1989; 16: 78-82.
254. Gray A, Morgan J. Liposomes in Haematology. Blood Rev 1991; 5: 258-272.
255. Gabizon AA. Liposomal Anthracyclines. Haematology/ Oncology Clinics of North America 1994; 8: 431-450.
256. Rahman A, Carmichael D, Harris M, Roh JK. Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Cancer Res 1986; 46: 2295-2299.
257. Mayer LD, Tai LCL, Ko DSC et al. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 1989; 49: 5922-5930.
258. Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 1992; 52: 891-896.
259. Forssen EA, Coulter DM, Proffitt RT. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res 1992; 52: 3255-3261.
260. Presant CA, Turner AF, Nadel H et al. Tumor targeted liposomes: implications of liposome (Vescan) imaging of primary and metastatic tumors for liposomal chemotherapy. Proc Am Soc Clin Oncol 1989; 8: 10 (abs 37).
261. Storm G, Roerdink FH, Steerenberg PA, de Jong WH, Crommelin DJ. Influence of lipid composition on the antitumour activity exerted by doxorubicin-containing liposomes in a rat solid tumour model. Cancer Res 1987; 47: 3366-3372
262. Gabizon A, Catane R, Uziely B et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987-992.
263. Huang SK, Lee K-D, Hong K, Friend DS, Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res 1992; 52: 5135-5143.
264. Huang SK, Martin FJ, Jay G et al. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am J Pathol 1993; 143: 10-14.
265. Forssen EA, Malé-Brune R, Adler-Moore JP et al. Fluroescence imaging studies for the disposition of daunorubicin liposomes (Daunoxome) within tumor tissue. Cancer Res 1996; 2066-2075.
266. Zou Y, Ling YH, Van NT, Priebe W, Perez Soler R. Antitumour activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties. Cancer Res 1994; 54: 1479-1484.
267. Kauter PM, Bullard GA, Giusberg RA et al. Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free oxidation in beagle dogs. In Vivo 1993; 7: 17-26.
268. Bally MB, Nayar R, Masin D et al. Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes. Cancer Chemother Pharmacol 1990; 27: 13-19
269. Olson F, Mayhew E, Maslow D, Rustum Y, Szoka F. Characterization of toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. Eur J Cancer Clin Oncol 1982; 18: 167-176.
270. Genne P, Olsson N-O, Gutierrez G, Duchamp O, Chauffert B. Liposomal mitoxantrone for the local treatment of peritoneal carcinomatosis induced by colon cancer cells in mice. Anti-cancer Drug Design 1994; 9: 73-84.
271. Zou Y, Ling Y-H, Van NT, Priebe W, Perez-Solar R. Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties. Cancer Res 1994; 54: 1479-1484.
272. Zou Y Ling Y-H, Reddy S, Priebe W, Perez Soler R. Effect of vesicle size and lipid composition on the in vivo tumor selectivity and toxicity of the non-cross-resistant anthracycline annamycin incorporated in liposomes. Int J Cancer 1995; 61: 666-671.
273. Wasan KM, Perez Soler R. Distribution of free and liposomal annamycin within human plasma is regulated by plasma triglyceride concentrations but not by lipid transfer protein. J Pharm Sci 1995; 84: 1094-110.